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Synthesis of brominated isobenzofuranones as new potent 
inhibitors of quorum sensing 
Li Linzi 
Department of Chemistry 
Seoul National University 
We designed and synthesized a series of brominated isobenzofuranone 
derivatives. These Compounds have significant biofilm inhibitory activities and are 
good candidates for quorum sensing inhibitors (QSIs). All of them can be 
synthesized simply within two steps. The optimization of the first step, gem-
dibromoolefination of phthalic anhydride, was done by replacing PPh3 with P(Oi-
Pr)3 and adding Zn dust, which significantly increased the reaction yields. After 
Stille coupling of an aryltin compound with the dibrominated furanone (A), a Z 
form isomer was obtained as a major product. The formation of the Z isomer was 
confirmed by 1H NMR spectroscopy and also single-crystal X-ray diffraction. 
According to the chemistry developed, a series of aryl-substituted bromofuranones 
were prepared and tested against quorum sensing inhibition. Out of these 
compounds tested, phenyl-substituted compound proved to be the most active one. 
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With emerging antibacterial multidrug resistance [1], traditional treatment of 
diseases is stagnating. Development of new therapeutic methods is being actively 
pursued all over the world. Recently a great deal of interest has been concentrated 
to the cell-to-cell communication among bacteria. This communication system, 
termed as quorum sensing (QS), depends on the density of bacteria population and 
works by detecting autoinducers. It controls many physiological activities including 
bioluminescence [2], symbiosis, virulence, motility, sporulation and biofilm 
formation [3]. Therefore inhibition of QS has become one of the most promising 
therapeutic approaches for disease control [4]. 
QS inhibitors (QSIs) reported so far can be mainly divided into three classes: 
proteins, peptides and nonpeptide small molecules. They can inhibit QS by acting 
as structural analogues of autoinducer receptors. Gram-negative bacteria use 
acylated homoserine lactones while Gram-positive bacteria use oligo-peptides as 
autoinducers to communicate within species. However, recent advances have 
shown that autoinducer-2 (AI-2) is an excellent QS molecule widely produced by 
various bacteria and can be used in intra-species as well as inter-species 
communication [5–7]. For example, AI-2 is the primary QS molecule produced by 
more than 700 species of oral bacteria as suggested by Kolenbrander [8]. He 
proposed that pathogens produce and receive much higher level of AI-2 than 
commensal bacteria, which enhances biofilm formation thus causing periodontitis. 
Synthesis of AI-2 molecules is related to the activity of enzyme LuxS. Zang et al. 
have reported that some natural brominated furanones can inhibit LuxS. The 




Scheme 1: mechanism proposed by Zang et al. [9,10] 
 
 
As our previous study has reported, AI-2 produced by Fusobacterium nucleatum, 
the main periodontopathogen, was reduced by QSIs [6]. It represents a new 
effective therapeutic strategy for periodontitis using QSI without disturbing other 
numerous oral commensals. Recently we also reported a new class of AI-2 quorum-
sensing inhibitors against bacterial biofilm formation [11]. It showed that the 
bicyclic structure is essential for good inhibitory activities. After succeeding in the 
synthesis of bicyclic dibrominated furanones, we have continued our investigation 
on new potent and safer candidates. We synthesized a series of monobrominated 




Ⅰ. Bicyclic dibrominated isobenzofuranones 
1. Chemistry 
We first designed and synthesized bicyclic dibrominated furanone derivatives 
with low toxicity but improved biofilm inhibitory activities. We synthesized two 
kinds of bicyclic brominated furanone derivatives by modification of the ring 
structure and side chain on the benzene ring. The ring structure has been reported 
to be important for good inhibition of biofilm formation [12]. Thus, compounds 
with different ring structures (QS-D:1–5) were designed for evaluation of the ring 
structure effect on the biofilm inhibitory activity. It has also been reported that 
monocyclic furanones with chain lengths of two to six atoms have good inhibitory 
activities [13,14]. Therefore, in order to investigate the effect of side chains, we 
designed another set of compounds with different chains on benzene ring 
According to the gem-dibromoolefination procedure [15], brominated 
compounds with various ring structures (QS-D:10–14) shown in Table 1 were 
synthesized from the corresponding commercially available compounds. The yields 
ranged from low to moderate (24–65% yields). However, the olefination products 
of cyclobutane-1,2-dicarboxylic anhydrides decomposed rapidly at room 
temperature presumably due to the unstable nature of the anhydrides based on the 












The substrates containing alkoxy groups on the benzene ring QS-D: 7a-7d and 
QS-D: 9a-9d were prepared from the corresponding phenol derivatives at moderate 
to good yields over four steps (45%-77%). Dibrominated compounds QS-D: 15-
18d with side chains on the benzene ring were obtained with 70-83% 
regioselectivity. As a similar study that examined the regioselectivity of Wittig 
reactions for phthalic anhydrides [17], this result showed that the electronic effects 
of the substituents appear to have a big influence on the regioselectivity. 
Compounds QS-D: 15–18d were obtained in overall 16% to 22% yields. Small 
amounts of minor isomers were produced from the anhydrides QS-D: 6–9d. 
However, we focused on the major products because they have much better 
inhibitory activity. All compounds were purified through column chromatography. 
The structures were all confirmed by 1H, 13C NMR, heteronuclear multiple bond 
correlation (HMBC), and mass spectrometry (MS). 
2. Biological assays 
In order to evaluate the inhibitory activities of these dibrominated furanones we 
synthesized, they were first screened for their inhibitory effects on the biofilm 
formation of F. nucleatum at 0.2 and 2 μM concentrations comparing with reference 
furanone compound R1. The Compound with 5-membered ring structure (QS-D: 
13) and the one with a short methyl chain on the benzene ring (QS-D: 15 and 17) 
showed high inhibitory effects on the biofilm formation than the others. Then we 
chose compounds QS-D: 13, 15 and 17 for further evaluation in the following 
biological assays. 
2.1  Inhibitory effect on the biofilm formation of major periodontopathogens 
We tested the inhibitory effect of the three compounds (QS-D: 13, 15 and 17) on 
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biofilm formation by observation using a confocal laser-scanning microscope.    
Three different periodontopathogens, F. nucleatum, P. gingivalis, and T. forsythia 
were grown on a cover slip. 
As shown below, compounds QS-D: 13, 15, and 17 at 2 μM significantly reduced 
the biofilm formation of periodontopathogens induced by F. nucleatum, P. 
gingivalis, and T. forsythia. The average depth of the biofilm formed on glass cover 
slips was analyzed using the Carl Zeiss LSM 700 program. Their inhibitory 
activities were all higher than Compound R1, which was reported as a good QSI, at 
all concentrations tested (0.002 - 2 μM). The inhibitory activities of compounds 
QS-D: 13 and 17 did not follow a dose-dependent tendency. The structure of the 
AI-2 receptor may be different among bacterial species [10,18]. The furanone 
compounds may act as partial agonists or antagonists depending on the 
concentration in accordance with the different structures of AI-2 receptors [19–21]. 
It is notable that the inhibitory activities of QS-D: 13, 15, and 17 against F. 
nucleatum biofilm formation are superior to those of the reference furanone 
compound even at very low concentration (2 nM). The inhibition of biofilm 
formation can obstruct the formation of a pathogenic biofilm, and thus prevent 




Fig. 1. Biofilm images showing the inhibitory effects of furanone compounds on the biofilm 
formation of F. nucleatum, P. gingivalis, and T. forsythia. (A) F. nucleatum (2 × 107 bacteria/mL), 
(B) P. gingivalis (2 × 108 bacteria/mL), and (C) T. forsythia (2 × 108 bacteria/mL) were cultured 
with semi-purified F. nucleatum AI-2 in the absence or presence of the reference furanone 
compound (Fur) or new furanone compounds (QS-D: 13, 15, and 17) at 2 µM under an anaerobic 
condition at 37°C. After 48 h incubation, each biofilm formed on glass cover slips was stained with 
the live/dead-BacLight bacterial viability kit followed by observation using a confocal laser-
13 
 
scanning microscope at 1000× magnification. The control group was the biofilm of each bacterium 
cultured without F. nucleatum AI-2 and inhibitors. 
Table 2. Biomass and depth of periodontopathogen biofilms. 
*p < 0.05 compared with the untreated group (Control), and #p < 0.05 compared with the F. 
nucleatum AI-2-treated value in the absence of furanone compounds. 
Fig.2. Inhibitory effects of furanone compounds on the biofilm formation of 
14 
 
periodontopathogens at various concentrations. (A) F. nucleatum (2 × 107 bacteria/mL), (B) P. 
gingivalis (2 × 108 bacteria/mL), and (C) T. forsythia (2 × 108 bacteria/mL) were cultured with 10% 
semi-purified F. nucleatum AI-2 in the presence of the reference furanone compound (Fur) or new 
furanone compounds (QS-D: 13, 15, and 17) at various concentrations for 48 h. Biofilm formation 
was assessed by crystal violet staining. *p < 0.05 compared with the non-treated value, and #p < 
0.05 compared to the F. nucleatum AI-2-treated value in the absence of furanone compounds. The 
experiments were performed three times in triplicate and representative data are shown. 
2.2 Inhibitory effect on AI-2 activity 
AI-2 activities were evaluated by measuring the AI-2 mediated bioluminescence 
of the bacteria using Vibrio harveyi BB170, an AI-2 reporter strain. An additional 
bacterial growth test showed us that the reference furanone compound significantly 
inhibited the growth of V. harveyi BB170 (Fig. 1B) by reducing bioluminescence. 
The new compounds QS-D: 13, 15, and 17, which have high inhibitory activities, 
were screened for their inhibitory effect on the AI-2 activity comparing with the 
reference furanone compound. As shown in Fig. 3, They significantly reduced the 
bioluminescence of V. harveyi BB170 at 2 μM, although their inhibitory activities 
were lower than that of the reference furanone compound (Fig. 3A). And at the 
same time, the newly synthesized compounds did not affect the planktonic growth 
of V. harveyi BB170. 
 
Fig. 3. Effect of furanone compounds on AI-2 activity and V. harveyi growth. (A) AI-2 activity 
was assessed by measuring bioluminescence using the AI-2 reporter strain V. harveyi BB170. V. 
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harveyi BB170 (1 × 106 bacteria/mL) was incubated for 6 h with 10% semi-purified F. nucleatum 
AI-2 in the absence or presence of furanone compounds (QS-D: 13, 15, and 17) and the reference 
furanone compound (Fur) at a concentration of 2 μM. The bioluminescence of V. harveyi BB170 
was measured using a luminometer and the value was converted to a percentage of the control value. 
*p < 0.05 compared to the value of the F. nucleatum AI-2-treated group. (B) V. harveyi BB170 was 
grown aerobically for 9 h in the absence of F. nucleatum AI-2 at 30°C in the presence of the 
reference furanone compound (Fur) or new furanone compounds (QS-D: 13, 15, and 17) at a 
concentration of 2 µM. Planktonic bacterial growth was monitored by measuring absorbance at 600 
nm using a spectrophotometer. *p < 0.05 compared to the untreated group (cont). The experiments 
were performed three times in triplicate and representative data are shown. 
2.3  Effect on planktonic bacterial growth 
QSIs selectively control virulence expression without disturbing bacterial growth. 
To confirm the new furanone compounds do not inhibit bacterial growth, we 
assessed their effects on planktonic bacterial growth. As shown in Fig. 4, the 
compounds did not inhibit the growth of F. nucleatum, P. gingivalis, and T. forsythia 
even at the highest concentration (2 µM) in the biofilm formation assay. 
 
Fig. 4. Effects of furanone compounds on bacterial growth. (A) F. nucleatum, (B) P. gingivalis, 
and (C) T. forsythia were grown for 48 h under anaerobic conditions at 37°C in the presence of the 
reference furanone compound (Fur) or new furanone compounds (QS-D: 13, 15, and 17) at a 





2.4  Cytotoxicity evaluation 
A cytotoxicity test demonstrated that the compounds did not affect host cell 
viability at 2 µM as shown in Fig. 5. The experiments were carried out in three types 
of human cells: the monocytic cell line THP-1, human gingival fibroblasts (HGFs), 
and the human oral keratinocyte cell line HOK-16B. 
 
Fig. 5. Effects of furanone compounds on host cell viability. (A) THP-1 cells (1 × 105 cells/well), 
(B) HGFs (2 × 104 cells /well), and (C) HOK-16B cells (5 × 104 cells/well) cultured in 96-well plates 
were treated with the reference furanone compound (Fur) and new furanone compounds (QS-D: 13, 
15, and 17) for 24 h, and the cell viability was detected using Cell Counting Kit-8. The control was 
the non-treated group. The experiments were performed three times in triplicate and representative 
data are shown. 
2.5  Effect on the host cell immune response 
The expression levels of proinflammatory cytokines, including interleukin (IL)-
6 and IL-8, were tested to evaluate whether the new compounds induce an 
inflammatory response in host cells. They were analyzed by real-time reverse 
transcription-polymerase chain reaction (RT-PCR) after treating THP-1 cells and 
HGFs with the furanone compounds. As shown in Fig. 6, both in THP-1 and HGFs, 
the new furanone compounds (QS-D: 13, 15, and 17) did not induce an 
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inflammatory response, whereas the reference furanone or lipopolysaccharide (LPS; 
1 µg/mL) significantly induced the gene expression of IL-6 and IL-8. 
 
Fig. 6. Effects of furanone compounds on proinflammatory cytokines. THP-1 cells (1 × 106 
cells/well, A and B) and HGFs (2 × 105 cells /well, C and D) cultured in 6-well plates were treated 
with the reference furanone compound (Fur) and new furanone compounds (QS-D: 13, 15, and 17) 
for 24 h. The expression levels of IL-6 and IL-8 mRNA were analyzed by real-time RT-PCR. The 
experiments were performed three times in triplicate, and representative data are shown. *p < 0.05 
compared to the untreated control value. 
3. Conclusion  
We synthesized bicyclic dirominated furanone derivatives and tested their 
biological inhibitory effects. Among these compounds tested, the one containing a 
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five-membered ring (QS-D:13) and the ones have methylbenzene moieties (QS-D: 
15 and 17) showed the best activities. They significantly inhibited the F. nucleatum 
AI-2 activity and biofilm formation of F. nucleatum, P. gingivalis, and T. forsythia 
without disturbing bacterial growth. The inhibitory activities of QS-D: 13, 15, and 
17 were similar to or better than that of the reference furanone. In addition, our new 
furanone compounds showed neither cytotoxicity nor induction of proinflammatory 
cytokine expression, whereas the reference furanone compound showed 
cytotoxicity and induced the expression of proinflammatory cytokines such as IL-
6 and IL-8 in human cells.  
Our results highlight the importance of the bicyclic structure for its effective 
biofilm inhibition activity. With emerging issues, such as antibacterial multidrug 
resistance, development of new therapeutic methods is being actively pursued all 
over the world. Inhibition of QS has become one of the most promising therapeutic 
approaches for disease control. In this study, it showed that the new furanone 
compounds QS-D: 13, 15, and 17 can be good candidates for preventing 
periodontitis.  
4. Experimental procedures  
The 1H, 13C NMR-spectra and heteronuclear multiple bond correlation (HMBC) 
were measured with an Agilent 400-MR DD2 Magnetic Resonance System (400 
MHz) and a Varian/Oxford As-500 (500 MHz) spectrophotometer. Chemical shifts 
were measured as parts per million (δ values) from tetramethylsilane as an internal 
standard at probe temperature in CDCl3 or DMSO-D6 for neutral compounds. 
Coupling constants are provided in Hz, with the following spectral pattern 
designations: s, singlet; d, doublet; t, triplet; q, quartet; quint, quintet; m, multiplet; 
br, broad; app, apparent. Reactions that needed anhydrous conditions were carried 
19 
 
out in flame-dried glassware under positive pressure of dry N2 using standard 
Schlenk line techniques. Evaporation of solvents was performed at reduced pressure 
using a rotary evaporator. TLC was performed using silica gel 60F254 coated on 
aluminum sheet (E. Merck, Art.5554). Column chromatography was performed on 
silica gel (Merck. 7734 or 9385 Kiesel gel 60), and eluent was mentioned in each 
procedure. High resolution mass spectra (HRMS) were recorded on a 
ThermoFinnigan LCQ™ Classic, Quadrupole Ion-Trap Mass Spectrometer. HPLC 
analyses were carried out on an Agilent HP1100 system (Santa Clara, CA, USA), 
composed of an auto sampler, quaternary pump, photodiode array detector (DAD), 
and HP Chemstation software. The separation was arried out on a poroshell 120 EC-
C18 column 4.6 × 50 mm i.d. (2.7 m particle size) with 0.1% TFA in water (A) 
and acetonitrile (B) as a mobile phase at a flow rate of 1 mL/min at 20 °C. Method: 
100% A and 0% B (0 min), 50% A and 50% B (5 min), 5% A and 95% B (15 min), 
5% A and 95% B (22 min), 100% A and 0% B (23 min), 100% A and 0% B (25 
min). Details are given below for one example of each reaction type; the syntheses 
and characterization of analogues are reported in the Supplementary Information. 
All materials were obtained from commercial supplier and used without further 
purification unless otherwise noted. 
4.1. General procedure for the preparation of 3 or 4-alkoxyphthalic anhydride (QS-
D: 7a–7e, 9a–9d) 
Following a reported procedure [26], add H2SO4 (0.054 mL, 1.02 mmol) to a 
stirred solution of 3- or 4-hydroxyphthalic acid (1.09 g, 6.00 mmol) in 12 mL of 
MeOH. The reaction was stirred at reflux overnight. Solvent was removed under 
reduced pressure and the solid residue obtained was dissolved in dichloromethane 
(40 mL) and washed with water (20 × 3 mL). The combined organic layer was dried 
20 
 
over anhydrous MgSO4, filtered and concentrated under reduced pressure to 
provide crude dimethyl 4-hydroxyphthalate. The crude dimethyl 3- or 4-
hydroxyphthalate was dissolved in 3 mL of acetone and K2CO3 (1.3 g, 9.5 mmol) 
was added to the solution. The mixture was stirred at room temperature for 1 h. 
Alkyl iodide (5.7 mmol) was added, and the mixture was stirred at reflux overnight. 
and the solvent was removed under reduced pressure to provide dimethyl 3- or 4-
alkoxyphthalate. 
A solution of dimethyl 3- or 4-alkoxyphthalate in 3 mL of acetone was treated 
with an aq solution of NaOH (0.34 g, 8.4 mmol) in 2 mL water and then the resulting 
solution was stirred at room temperature overnight. After evaporation of the solvent, 
the mixture was acidified with 6 M HCl to pH 2 and concentrated under reduced 
pressure. Then, the 3- or 4-alkoxyphthalic acid was dissolved in 4 mL of Ac2O and 
the solution was heated at reflux for 18 h. Upon cooling to room temperature, the 
resulting solution was concentrated by rotary evaporation and then the residue was 
purified with flash column chromatography. The desired products QS-D: 
7a-7e and 9a–9d were obtained.  
4.1.1. 4-Methoxyphthalic anhydride (QS-D: 7a). Yield 0.80 g (75%). 1H NMR 
(DMSO-d6, 500 MHz) δ 7.99 (d, J = 8.4 Hz, 1H), 7.58 (d, J = 2.3 Hz, 1H), 7.48 (dd, 
J = 8.5, 2.3 Hz, 1H), 3.97 (s, 3H). 13C NMR (DMSO-d6, 125 MHz) δ 165.7, 163.1, 
162.7, 134.0, 127.2, 122.9, 122.7, 109.3, 56.7. 
4.1.2. 4-Ethoxyphthalic anhydride (QS-D: 7b). Yield 0.83 g (72%). 1H NMR 
(DMSO-d6, 500 MHz) δ 7.96 (d, J = 8.4 Hz, 1H), 7.53 (d, J = 2.3 Hz, 1H), 7.45 (dd, 
J = 8.4, 2.3 Hz, 1H), 4.25 (q, J = 7.0 Hz, 2H), 1.37 (t, J = 7.0 Hz, 3H). 13C NMR 
(DMSO-d6, 125 MHz) δ 164.92, 163.1, 162.6, 134.0, 127.2, 123.1, 122.5, 109.6, 
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64.9, 14.3.  
4.1.3. 4-Propoxyphthalic anhydride (QS-D: 7c). Yield 0.86 g (70%). 1H NMR 
(DMSO-d6, 500 MHz) δ 7.97 (d, J = 8.4 Hz, 1H), 7.55 (d, J = 2.2 Hz, 1H), 7.47 (dd, 
J = 8.4, 2.3 Hz, 1H), 4.16 (t, J = 6.5 Hz, 2H), 1.81 – 1.72 (m, 2H), 0.99 (t, J = 7.4 
Hz, 3H). 13C NMR (DMSO-d6, 125 MHz) δ 165.1, 163.1, 162.7, 134.0, 127.2, 
123.1, 122.5, 109.6, 70.5, 21.7, 10.2. 
4.1.4. 4-Butoxyphthalic anhydride (QS-D: 7d). Yield 0.97 g (74%). 1H NMR 
(DMSO-d6, 500 MHz) δ 7.97 (d, J = 8.4 Hz, 1H), 7.56 (d, J = 2.3 Hz, 1H), 7.47 (dd, 
J = 8.5, 2.2 Hz, 1H), 4.20 (t, J = 6.5 Hz, 2H), 1.79 – 1.68 (m, 2H), 1.51 – 1.38 (m, 
2H), 0.94 (t, J = 7.4 Hz, 3H). 13C NMR (DMSO-d6, 125 MHz) δ 165.1, 163.1, 
162.7, 134.0, 127.2, 123.2, 122.5, 109.6, 68.8, 30.3, 18.6, 13.6. 
4.1.5. 4-Pentyloxyphthalic anhydride (QS-D: 7e). Yield 0.98 g (70%). 1H NMR 
(DMSO-d6, 500 MHz) δ 7.96 (d, J = 8.4 Hz, 1H), 7.55 (d, J = 2.2 Hz, 1H), 7.46 (dd, 
J = 8.4, 1.8 Hz, 1H), 4.19 (t, J = 6.5 Hz, 2H), 1.82 – 1.69 (m, 2H), 1.47 – 1.28 (m, 
4H), 0.90 (t, J = 7.1 Hz, 3H). 
4.1.6. 3-Ethoxyphthalic anhydride (QS-D: 9a). Yield 0.61 g (53%). 1H NMR 
(DMSO-d6, 500 MHz) δ 7.92 (dd, J = 8.5, 7.4 Hz, 1H), 7.58 (dd, J = 16.4, 7.9 Hz, 
2H), 4.31 (q, J = 7.0 Hz, 2H), 1.40 (t, J = 7.0 Hz, 3H). 13C NMR (DMSO-d6, 125 
MHz) δ 163.2, 160.6, 156.9, 138.7, 133.0, 120.2, 116.8, 116.4, 65.0, 14.3. 
4.1.7. 3-Propoxyphthalic anhydride (QS-D: 9b). Yield 0.58 g (47%). 1H NMR 
(DMSO-d6, 500 MHz) δ 7.92 (dd, J = 8.4, 7.4 Hz, 1H), 7.60 (d, J = 8.5 Hz, 1H), 
7.56 (d, J = 7.4 Hz, 1H), 4.20 (t, J = 6.4 Hz, 2H), 1.85 – 1.75 (m, 2H), 1.02 (t, J = 
7.4 Hz, 3H). 13C NMR (DMSO-d6, 125 MHz) δ 163.2, 160.6, 157.1, 138.7, 133.0, 
120.3, 116.8, 116.4, 70.5, 21.7, 10.1. 
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4.1.8. 3-Butoxyphthalic anhydride (QS-D: 9c). Yield 0.59 g (45%). 1H NMR 
(DMSO-d6, 500 MHz) δ 7.91 (dd, J = 8.4, 7.4 Hz, 1H), 7.60 (d, J = 8.5 Hz, 1H), 
7.56 (d, J = 7.3 Hz, 1H), 4.24 (t, J = 6.4 Hz, 2H), 1.82 – 1.71 (m, 2H), 1.54 – 1.42 
(m, 2H), 0.95 (t, J = 7.4 Hz, 3H). 13C NMR (DMSO-d6, 125 MHz) δ 163.2, 160.5, 
157.1, 138.7, 133.0, 120.2, 116.8, 116.4, 68.8, 30.3, 18.5, 13.6.  
4.1.9 3-Pentyloxyphthalic anhydride (QS-D: 9d). Yield 0.64 g (46%). 1H NMR 
(DMSO-d6, 500 MHz) δ 7.91 (dd, J = 8.4, 7.4 Hz, 1H), 7.60 (d, J = 8.5 Hz, 1H), 
7.55 (d, J = 7.4 Hz, 1H), 4.23 (t, J = 6.5 Hz, 2H), 1.79 (dd, J = 14.1, 7.3 Hz, 2H), 
1.52 – 1.30 (m, 4H), 0.90 (t, J = 7.2 Hz, 3H). 13C NMR (DMSO-d6, 125 MHz) δ 
163.2, 160.5, 157.1, 138.7, 133.0, 120.2, 116.8, 116.4, 69.1, 28.0, 27.4, 21.8, 13.9. 
  
4.2. General procedure for the preparation of bicyclic brominated furanone 
derivatives (QS-D: 10– 18d) 
Triphenylphosphine (1.60 g, 6.00 mmol) was dissolved in 6 mL of THF and the 
solution was cooled to 0 °C under Ar. A solution of CBr4 (1.00 g, 3.00 mmol) in 
THF (1.00 mL per mmol PPh3) was added to the THF (6 mL) solution of PPh3 and 
the reaction was stirred until the color changed to yellow. Triethylamine (TEA) (1.1 
mL, 6.0 mmol) was added dropwise to the mixture over 5 min, then a solution of 
an anhydride compound (QS-D: 1–9d, 1.00 mmol) in THF (1.0 mL per mmol 
phthalic anhydride) was added. The reaction was stirred for 1 h at 0 °C, after which 
it was allowed to warm to room temperature and stirred overnight. The reaction was 
quenched by addition of sat aq. NH4Cl solution (3 mL). The phases were then 
separated, and the crude product was extracted with hexane from the aqueous layer 
(3 × 30 mL). The combined organic layers were concentrated under reduced 
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pressure. The residue was dissolved in Et2O (25 mL) and filtered over a Celite pad 
(7.0 × 3.0 cm). The resulting filtrate was concentrated by rotary evaporation and 
the crude products were purified through the column chromatography (5–15% 
EtOAc in hexane).  
4.2.1 3-(Dibromomethylene)isobenzofuran-1(3H)-one (QS-D: 10). Yield 0.091 g 
(30%). 1H NMR (DMSO-d6, 500 MHz) δ 8.32 (d, J = 8.0 Hz, 1H, H-4), 7.95 (d, J 
= 7.6 Hz, 1H, H-7), 7.90 (t, J = 7.7 Hz, 1H, H-5), 7.75 (t, J = 7.5 Hz, 1H, H-6). 13C 
NMR (DMSO-d6,125 MHz) δ 164.0 (C-1), 145.5 (C-3), 135.8 (C-3a), 135.6 (C-5), 
131.4 (C-6), 126.0 (C-7), 125.3 (C-7a), 123.7 (C-4), 77.3 (=CBr2). HRMS (ESI) 
m/z: Anal. calcd. for [M+Na]+ C9H4Br2NaO2+: 324.8470; found 324.8471. 
4.2.2 3-(Dibromomethylene)hexahydroisobenzofuran-1(3H)-one (QS-D:11). Yield 
0.12 g (40%). 1H NMR (CDCl3, 500 MHz) δ 3.31 – 3.19 (m, 1H), 2.98 (t, J = 6.8 
Hz, 1H), 2.22 (t, J = 14.3 Hz, 2H), 1.72 (d, J = 15.0 Hz, 2H), 1.35 – 1.05 (m, 4H). 
13C NMR (CDCl3, 125 MHz) δ 174.1, 158.2, 68.9, 40.7, 40.0, 26.5, 23.0, 22.3. 
HRMS (ESI) m/z: Anal. calcd. for [M+Na]+ C9H10Br2NaO2+: 330.8940; found 
330.8942. 
4.2.3 3-(Dibromomethylene)-4,5,6,7-tetrahydroisobenzofuran-1(3H)-one (QS-D 
12). Yield 0.20 g (65%). 1H NMR (DMSO-d6, 500 MHz) δ 2.74 – 2.69 (m, 2H), 
2.16 – 2.11 (m, 2H), 1.72 – 1.68 (m, 2H), 1.63 – 1.59 (m, 2H). 13C NMR (DMSO-
d6, 125 MHz) δ 166.5, 149.7, 148.6, 131.2, 78.4, 25.0, 21.3, 20.5, 20.1. HRMS (ESI) 
m/z: Anal. calcd. for [M+Na]+ C9H8Br2NaO2+: 328.8783; found 328.8786. 
4.2.4. 3-(Dibromomethylene)hexahydro-1H-cyclopenta[c]furan-1-one (QS-D 13). 
Yield 0.071 g (24%). 1H NMR (DMSO-d6, 500 MHz) δ 3.50 – 3.48 (m, 2H), 2.04 
– 1.82 (m, 4H), 1.73 – 1.66 (m, 1H), 1.39 – 1.30 (m, 1H). 13C NMR (DMSO-d6, 125 
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MHz) δ 176.5, 155.4, 68.0, 45.8, 43.8, 32.2, 30.8, 25.6. HRMS (ESI) m/z: Anal. 
calcd. for [M+Na]+ C8H8Br2NaO2+: 316.8783; found 316.8780. 
4.2.5. 3-(Dibromomethylene)-3,4,5,6-tetrahydro-1H-cyclopenta[c]furan-1-one 
(QS-D: 14). Yield 0.080 g (27%). 1H NMR (DMSO-d6, 500 MHz) δ 2.96 – 2.91 (m, 
2H), 2.48 – 2.39 (m, 4H). 13C NMR (DMSO-d6, 125 MHz) δ 162.5, 162.2, 146.5, 
140.9, 79.4, 29.5, 28.1, 25.1. HRMS (ESI) m/z: Anal. calcd. for [M+Na]+ 
C8H6Br2NaO2+: 314.8627; found 314.8625. 
4.2.6. 3-(Dibromomethylene)-5-methylisobenzofuran-1(3H)-one (QS-D:15). Yield 
0.076 g (24%). 1H NMR (DMSO-d6, 500 MHz) δ 8.18 (s, 1H, H-4), 7.87 (d, J = 7.9 
Hz, 1H, H-7), 7.60 (d, J = 7.8 Hz, 1H, H-6), 2.52 (s, 3H, -CH3).
 13C NMR (DMSO-
d6, 125 MHz) δ 164.0 (C-1), 146.9 (C-5), 145.5 (C-3), 136.3 (C-3a), 132.6 (C-6), 
126.0 (C-7), 124.0 (C-4), 122.9 (C-7a), 77.0 (=CBr2), 22.0 (-CH3). HRMS (ESI) 
m/z: Anal. calcd. for [M+Na]+ C10H6Br2NaO2+: 338.8627; found 338.8629. 
4.2.7. 3-(Dibromomethylene)-5-methoxyisobenzofuran-1(3H)-one (QS-D:16a). 
Yield 0.073 g (22%). 1H NMR (DMSO-d6, 500 MHz) δ 7.91 (d, J = 8.5 Hz, 1H, H-
7), 7.76 (s, 1H, H-4), 7.32 (d, J = 7.0 Hz, 1H, H-6), 3.93 (s, 3H, -OCH3).
 13C NMR 
(DMSO-d6, 125 MHz) δ 165.0 (C-5), 163.5 (C-1), 145.1 (C-3), 138.2 (C-3a), 127.9 
(C-7), 118.2 (C-6), 117.5 (C-7a), 108.2 (C-4), 77.4 (=CBr2), 56.2 (-OCH3). HRMS 
(ESI) m/z: Anal. calcd. for [M+Na]+ C10H6Br2NaO3+: 354.8576; found 354.8576. 
4.2.8. 3-(Dibromomethylene)-5-ethoxyisobenzofuran-1(3H)-one (QS-D:16b). 
Yield 0.70 g (20%). 1H NMR (DMSO-d6, 500 MHz) δ 7.90 (d, J = 8.5 Hz, 1H, H-
7), 7.76 (s, 1H, H-4), 7.31 (d, J = 7.0 Hz, 1H, H-6), 4.20 (q, J = 6.8 Hz, 2H, -OCH2), 
1.39 (t, J = 6.9 Hz, 3H, -CH3).
 13C NMR (DMSO-d6, 125 MHz) δ 164.3 (C-5), 163.6 
(C-1), 145.2 (C-3), 138.2 (C-3a), 128.0 (C-7), 118.4 (C-6), 117.3 (C-7a), 108.7 (C-
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4), 77.4 (=CBr2), 64.6 (-OCH2), 14.3 (-CH3). HRMS (ESI) m/z: Anal. calcd. for 
[M+Na]+ C11H8Br2NaO3+: 368.8732; found 368.8731. 
4.2.9. 3-(Dibromomethylene)-5-propoxyisobenzofuran-1(3H)-one (QS-D:16c). 
Yield 0.69 g (19%). 1H NMR (DMSO-d6, 500 MHz) δ 7.89 (d, J = 8.5 Hz, 1H, H-
7), 7.75 (s, 1H, H-4), 7.31 (d, J = 8.5 Hz, 1H, H-6), 4.09 (t, J = 6.4 Hz, 2H, -OCH2), 
1.84 – 1.75 (m, 2H, -CH2), 1.00 (t, J = 7.4 Hz, 3H, -CH3).
 13C NMR (DMSO-d6, 
125 MHz) δ 164.4 (C-5), 163.5 (C-1), 145.1 (C-3), 138.1 (C-3a), 127.9 (C-7), 118.5 
(C-6), 117.3 (C-7a), 108.7 (C-4), 77.4 (=CBr2), 70.2 (-OCH2), 21.8(-CH2), 10.3(-
CH3). HRMS (ESI) m/z: Anal. calcd. for [M+Na]+ C12H10Br2NaO3+: 382.8889; 
found 382.8887. 
4.2.10. 3-(Dibromomethylene)-5-butoxyisobenzofuran-1(3H)-one (QS-D:16d). 
Yield 0.79 g (21%). 1H NMR (DMSO-d6, 500 MHz) δ 7.90 (d, J = 8.5 Hz, 1H, H-
7), 7.76 (s, 1H, H-4), 7.31 (d, J = 8.5 Hz, 1H, H-6), 4.14 (t, J = 6.4 Hz, 2H, -OCH2), 
1.80 – 1.68 (m, 2H, -CH2), 1.50 – 1.39 (m, 2H, -CH2), 0.94 (t, J = 7.4 Hz, 3H, -
CH3).
 13C NMR (DMSO-d6, 125 MHz) δ 164.4 (C-5), 163.5 (C-1), 145.2 (C-3), 
138.2 (C-3a), 128.0 (C-7), 118.4 (C-6), 117.3 (C-7a), 108.7 (C-4), 77.4 (=CBr2), 
68.4 (-OCH2), 39.5 (-CH2), 30.4 (-CH2), 18.6 (-CH2), 13.6 (-CH3). HRMS (ESI) 
m/z: Anal. calcd. for [M+Na]+ C13H12Br2NaO3+: 396.9045; found 396.9047. 
4.2.11. 3-(Dibromomethylene)-5-(pentyloxy)isobenzofuran-1(3H)-one (QS-D 16e). 
Yield 0.74 g (19%). 1H NMR (DMSO-d6, 500 MHz) δ 7.88 (d, J = 8.5 Hz, 1H, H-
7), 7.74 (s, 1H, H-4), 7.30 (d, J = 8.6 Hz, 1H, H-6), 4.12 (t, J = 6.4 Hz, 2H, -OCH2), 
1.81 – 1.72 (m, 2H, -CH2), 1.46 – 1.29 (m, 4H, -CH2), 0.90 (t, J = 7.1 Hz, 3H, -
CH3).
 13C NMR (DMSO-d6, 125 MHz) δ 164.4 (C-5), 163.5 (C-1), 145.1 (C-3), 
138.1 (C-3a), 127.9 (C-7), 118.4 (C-6), 117.3 (C-7a), 108.7 (C-4), 77.4 (=CBr2), 
68.7 (-CH2), 28.1 (-CH2), 27.5 (-CH2), 21.8 (-CH2), 13.9(-CH3). HRMS (ESI) m/z: 
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Anal. calcd. for [M+Na]+ C14H14Br2NaO3+: 410.9202; found 410.9203. 
4.2.12. 3-(Dibromomethylene)-7-methylisobenzofuran-1(3H)-one (QS-D:17). 
Yield 0.83 g (26%). 1H NMR (DMSO-d6, 500 MHz) δ 8.18 (d, J = 7.9 Hz, 1H, H-
4), 7.77 (t, J = 7.7 Hz, 1H, H-5), 7.55 (d, J = 7.5 Hz, 1H, H-6), 2.61 (s, 3H). 13C 
NMR (DMSO-d6, 125 MHz) δ 164.0 (C-1), 145.2 (C-3), 139.8 (C-7), 136.1 (C-3a), 
135.2 (C-5), 132.9 (C-6), 122.8 (C-7a), 121.3 (C-4), 76.5 (=CBr2), 16.9 (-CH3). 
HRMS (ESI) m/z: Anal. calcd. for [M+Na]+ C10H6Br2NaO2+: 338.8627; found 
338.8628. 
4.2.13. 3-(Dibromomethylene)-7-ethoxyisobenzofuran-1(3H)-one (QS-D: 18a). 
Yield 0.66 g (19%). 1H NMR (DMSO-d6, 500 MHz) δ 7.87 (d, J = 7.8 Hz, 1H, H-
4), 7.82 (t, J = 8.0 Hz, 1H, H-5), 7.32 (d, J = 8.2 Hz, 1H, H-6), 4.24 (q, J = 6.9 Hz, 
2H, -OCH2), 1.38 (t, J = 7.0 Hz, 3H, -CH3).
 13C NMR (DMSO-d6, 125 MHz) δ 
161.4 (C-1), 157.8 (C-7), 145.1 (C-3), 137.8 (C-5), 137.7 (C-3a), 115.3 (C-4), 114.7 
(C-6), 111.8 (C-7a), 76.7 (=CBr2), 64.6 (-OCH2), 14.3 (-CH3). HRMS (ESI) m/z: 
Anal. calcd. for [M+Na]+ C11H8Br2NaO3+: 368.8732; found 368.8733. 
4.2.14. 3-(Dibromomethylene)-7-propoxyisobenzofuran-1(3H)-one (QS-D: 18b). 
Yield 0.65 g (18%). %). 1H NMR (DMSO-d6, 500 MHz) δ 7.87 (d, J = 7.8 Hz, 1H, 
H-4), 7.82 (t, J = 8.0 Hz, 1H, H-5), 7.32 (d, J = 8.3 Hz, 1H, H-6), 4.13 (t, J = 6.4 
Hz, 2H, -OCH2), 1.85 – 1.73 (m, 2H, -CH2), 1.01 (t, J = 7.4 Hz, 3H, -CH3).
 13C 
NMR (DMSO-d6, 125 MHz) δ 161.4 (C-1), 157.9 (C-7), 145.1 (C-3), 137.8 (C-5), 
137.7 (C-3a), 115.4 (C-4), 114.8 (C-6), 111.9 (C-7a), 76.7 (=CBr2), 70.1 (-OCH2), 
21.8 (-CH2), 10.2 (-CH3). HRMS (ESI) m/z: Anal. calcd. for [M+Na]+ 
C12H10Br2NaO3+: 382.8889; found 382.8891. 
4.2.15. 3-(Dibromomethylene)- 7-butoxyisobenzofuran-1(3H)-one (QS-D: 18c). 
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Yield 0.68 g (18%). 1H NMR (DMSO-d6, 500 MHz) δ 7.88 (d, J = 7.8 Hz, 1H, H-
4), 7.82 (t, J = 8.0 Hz, 1H, H-5), 7.33 (d, J = 8.3 Hz, 1H, H-6), 4.18 (t, J = 6.4 Hz, 
2H, -OCH2), 1.80 – 1.66 (m, 2H, -CH2), 1.53 – 1.37 (m, 2H, -CH2), 0.94 (t, J = 7.4 
Hz, 3H, -CH3).
 13C NMR (DMSO-d6, 125 MHz) δ 161.4 (C-1), 157.9 (C-7), 145.1 
(C-3), 137.9 (C-5), 137.7 (C-3a), 115.4 (C-4), 114.8 (C-6), 111.9 (C-7a), 76.7 
(=CBr2), 68.5 (-CH2), 30.4 (-CH2), 18.6 (-CH2), 13.7 (-CH3). HRMS (ESI) m/z: 
Anal. calcd. for [M+Na]+ C13H12Br2NaO3+: 396.9045; found 396.9047. 
4.2.16. 3-(Dibromomethylene)-7-(pentyloxy)isobenzofuran-1(3H)-one (QS-D: 
18d). Yield 0.62 g (16%) 1H NMR (DMSO-d6, 500 MHz) δ 7.89 (d, J = 7.8 Hz, 1H, 
H-4), 7.83 (t, J = 8.0 Hz, 1H, H-5), 7.34 (d, J = 8.3 Hz, 1H, H-6), 4.18 (t, J = 6.5 
Hz, 2H, -OCH2), 1.84 – 1.70 (m, 2H, -CH2), 1.50 – 1.28 (m, 4H, -CH2CH2), 0.89 
(t, J = 7.2 Hz, 3H, -CH3).
 13C NMR (DMSO-d6, 125 MHz) δ 161.4 (C-1), 157.9 (C-
7), 145.1 (C-3), 137.9 (C-5), 137.7 (C-3a), 115.4 (C-4), 114.8 (C-6), 111.9 (C-7a), 
76.6 (=CBr2), 68.8 (-CH2), 28.0 (-CH2), 27.5 (-CH2), 21.8 (-CH2), 13.9 (-CH3). 
HRMS (ESI) m/z: Anal. calcd. for [M+Na]+ C14H14Br2NaO3+: 410.9202; found 
410.9201. 
Ⅱ. Bicyclic monobrominated furanones 
1. Chemistry 
We continued to study a series of monobrominated furanone derivatives, which 
were expected to have biofilm inhibitory activities. All of them were synthesized 
by only two steps. Although the first step, gem-dibromoolefination of phthalic 
anhydride, which was carried out according to our previous method, gave the 
expected product, nevertheless the yields were not appreciably high. Therefore, 
optimization was done first in this work. Inspired by the work of Y.-Q. Fang et 
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al.[27], replacing triphenylphosphine with triisopropyl phosphite, not only reduced 
the waste of reagents but also increased yields. After a series of experiments, we 
found that with the addition of zinc dust in THF, the reaction were complete in only 
30 minutes with satisfactory yields of the desired products. 
 
 




Table 3: Optimization of reaction conditions 
 
 
Scheme 3: Synthesis of tin compounds. 
 
 
Then monobrominated furanone derivatives were all obtained through Stille 
coupling reaction. Tin reagents from entries 5 and 6 were prepared according to the 
method reported by D.Y. Wang et al. [28], and the others were all obtained from 
commercial supplier and used as received. The upfield chemical shift of 1H of the 
aromatic ring next to the olefin demonstrates that Z-form isomer is the major 
product. And only Z-form product was found in some reactions as shown below in 
Table 3 (entries 1-6, and 10). The structure of compound QS-M 1 was also 
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confirmed by single-crystal X-ray diffraction experiment (Fig 8). Achim Sorg et al. 
and Vladislav Kotek et al. also obtained Z-form isomers as major products in their 
work [29–31].  
We believe that regioselectivity occurs during oxidative addition step (Scheme 
4). To understand this, notice that σC-O is a better donor than σC-C, which can 
make C-Br1 bond longer than C-Br2 bond. Additionally, we calculated the bond-
dissociation energy (D0) of C-Br
1 and C-Br2 ( Fig 8) and found that C-Br1 bond is 
weaker than C-Br2 bond. This lends further credence to our belief. All the 
computational calculations in this work were performed using the Gaussian 09 
program package with B3LYP hybrid functional. The 6-31G(d) basis set was used 
for all atoms. 
 
 





































Table 4: Synthesis of monobrominated furanone derivatives (QS-M) 
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2. Biological assays 
The Compound QS-M 1, which was confirmed by single-crystal X-ray 
diffraction, was first tested for its inhibitory activity in comparison with the 
reference furanone R1, QS-131 and QS-106 (which have highest activities in our 
previous work). As shown in Fig 8, compound QS-M 1 (QLZ) also showed 
significant inhibitory activity. 
 
Fig 9. Inhibitory effects of 1 on the biofilm formation of periodontopathogens at various 
concentrations. 
 
Table 5: Biofilm formation (% of control ) of 1( QS-LLZ ) comparing with furanone, Q106 
and Q131 
All the monobrominated furanones (QS-M: 1-13) were screened for their 
inhibitory effects on the biofilm formation of F. nucleatum at 0.2 μM concentrations 
together with R1. Among these compounds, QS-M: 1 and 11 showed better 





Fig. 10. Biofilm formation (% of control) of 1-13 in comparison with R1 
 






We designed and synthesized a series of monobrominated isobenzofuranone 
derivatives. All of them can be synthesized simply in two steps. The optimization 
of the first step, gem-dibromoolefination of phthalic anhydride, was done by 
replacing PPh3 with P(Oi-Pr)3 and adding Zn dust. After Stille coupling of this 
dibrominated furanone (A), a Z form isomer was obtained as a major product. This 
is confirmed by 1H NMR and also single crystal X-ray diffraction. 
These compounds were screened for their inhibitory effects on the biofilm 
formation of F. nucleatum at 0.2 μM concentrations in reference with R1. Among 
these compounds, QS-M: 1 and 11 showed most pronounced inhibitory activities. 
4. Experimental procedures 
The 1H, 13C NMR-spectra were measured with an Agilent 400-MR DD2 
Magnetic Resonance System (400 MHz) spectrophotometer and a Varian/Oxford 
As-500 (500 MHz) spectrophotometer. Chemical shifts were measured as part per 
million (δ values) from tetramethylsilane(TMS) as an internal standard at probe 
temperature in DMSO-D6 for neutral compounds. Coupling constants are provided 
in Hz, with the following spectral pattern designations: s, singlet; d, doublet; t, 
triplet; q, quartet; quint, quintet; m, multiplet; br, broad; app, apparent. Reactions 
that needed anhydrous conditions were carried out in flame-dried glassware under 
positive pressure of dry Ar using standard Schlenk line techniques. Evaporation of 
solvents was performed at reduced pressure using a rotary evaporator. TLC was 
performed using silica gel 60F254 coated on aluminum sheet (E. Merck, Art.5554). 
Column chromatography was performed on silica gel (Merck. 7734 or 9385 Kiesel 
gel 60). High resolution mass spectra (HRMS) were recorded on a ThermoFinnigan 
LCQ™ Classic, Quadrupole Ion-Trap Mass Spectrometer. HPLC analyses were 
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carried out on an Agilent HP1100 system (Santa Clara, CA, USA), composed of an 
auto sampler, quaternary pump, photodiode array detector (DAD), and HP 
Chemstation software. Phthalic anhydride was used after recrystallization and 
Tetrabromomethane was used after dried over MgSO4. All materials were obtained 
from commercial supplier. 
 
4.1. General procedure for the preparation of (A) 
Triisopropylphosphite (2.7 ml, 5.00 mmol) in 10 mL of THF with Zn dust (490 
mg, 7.50 mmol) was cooled to 0 °C under Ar. A solution of CBr4 (2.49 g, 7.50 mmol) 
in THF was added to the solution of P(Oi-Pr)3 and the reaction was stirred until the 
color changed to yellow. Then a solution of phthalic anhyride in THF was added. 
The reaction was stirred for 30 minutes at room temperature. After quenched by 
addition of sat aq NaHCO3 solution (2.5 mL), The phases were then separated, and 
the crude product was extracted with either from the aqueous layer. The residue was 
dissolved in either and filtered over a Celite pad. The resulting filtrate was 
concentrated by rotary evaporation and the desired products were obtained after 
purification by column chromatography (1–5% Either in hexane). 
4.1.1. 3-(dibromomethylene)isobenzofuran-1(3H)-one (A). Yield 62%. 1H NMR 
(DMSO-d6, 400 MHz) δ 8.36 (d, J = 8.0 Hz, 1H), 7.97 (d, J = 7.7 Hz, 1H), 7.91 (t, 
J = 8.0 Hz 1H), 7.75 (t, J = 8.0 Hz, 1H). 13C NMR (DMSO-d6, 100 MHz) δ 164.53, 
146.01, 136.32, 136.17, 131.93, 126.55, 125.86, 124.24, 77.69. 
4.2. General procedure for the preparation of (QS-M: 1-12) 
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Under an argon atmosphere, A (152 mg, 0.5 mmol), AsPh3(150 mg, 0.1 mmol), 
Pd(dba)2. (14 mg, 0.025 mmol), and THF (4 ml) were added to an oven-dried 
Schlenk tube. RSnBu3 (0.25 mmol) was added to the stirring mixture and then the 
mixture was heated to 66 oC for 24 h. The reaction mixture was cooled to room 
temperature and extracted with DCM (10 mL), washed brine, dried over MgSO4, 
and filtered. The crude material was purified by flash chromatography on silica gel. 
4.2.1 (Z)-3-(bromo(phenyl)methylene)isobenzofuran-1(3H)-one (QS-M: 1) Yield 
72%. 1H NMR (DMSO-d6, 500 MHz) δ 7.94 (d, J = 8.0 Hz, 1H), 7.66 – 7.54 (m, 
7H), 6.56 (d, J = 7.8 Hz, 1H). 13C NMR (DMSO-d6,125 MHz) δ 165.56, 144.65, 
137.05, 136.15, 135.62, 131.27, 130.87, 130.15, 129.97, 126.11, 125.32, 122.47, 
104.65. for [M+Na]+ C15H9BrNaO2
+: 322.9678; found 322.9678. 
4.2.2 (Z)-3-(bromo(thiophen-2-yl)methylene)isobenzofuran-1(3H)-one (QS-M: 2) 
Yield 65%. 1H NMR (DMSO-d6, 500 MHz) δ 7.97 (d, J = 5.2 Hz, 2H), 7.74 – 7.62 
(m, 2H), 7.50 – 7.44 (m, 1H), 7.26 (t, J = 4.3 Hz, 1H), 6.83 (d, J = 7.0 Hz, 1H).13C 
NMR (DMSO-d6,100 MHz) δ 165.25, 146.30, 137.14, 136.74, 135.82, 131.69, 
131.59, 131.40, 128.59, 126.18, 125.38, 122.66, 96.26. for [M+Na]+ 
C13H7BrNaO2S
+: 328.9242; found 328.9242. 
4.2.3 (Z)-3-(bromo(furan-2-yl)methylene)isobenzofuran-1(3H)-one (QS-M:3) 
Yield 62%. 1H NMR (DMSO-d6, 400 MHz) δ 8.02 (s, 1H), 7.98 (d, J = 7.5 Hz, 1H), 
7.75 (m, 2H), 7.34 (d, J = 7.9 Hz, 1H), 7.03 (d, J = 3.3 Hz, 1H), 6.80 – 6.74 (m, 1H). 
13C NMR (DMSO-d6,125 MHz) δ 165.13, 146.74, 146.04, 136.34, 135.96, 131.88, 
126.24, 125.45, 123.02, 115.35, 112.89, 93.11, 79.25. for [M+Na]+ C13H7BrNaO3
+: 
312.9470; found 312.9471. 
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4.2.4 (Z)-3-(bromo(4-chlorophenyl)methylene)isobenzofuran-1(3H)-one (QS-M: 4) 
Yield 59%. 1H NMR (DMSO-d6, 400 MHz) δ 7.96 (m, 1H), 7.71 – 7.59 (m, 6H), 
6.83 – 6.50 (m, 1H). 13C NMR (DMSO-d6,125 MHz) δ 165.49, 145.00, 136.88, 
135.83, 135.58, 135.04, 132.16, 131.41, 130.13, 126.17, 125.34, 122.62, 103.14. 
for [M+H]+ C15H9BrClNaO2
+: 334.9469; found 334.9469. 
4.2.5 (Z)-3-(bromo(4-chlorophenyl)methylene)isobenzofuran-1(3H)-one (QS-M: 5) 
Yield 75%. 1H NMR (DMSO-d6, 500 MHz) δ 7.97 – 7.90 (m, 1H), 7.63 (m, 4H), 
7.46 – 7.38 (m, 2H), 6.64 – 6.56 (m, 1H). 13C NMR (DMSO-d6,125 MHz) δ 165.53, 
163.40 (d, J = 248.6 Hz), 144.93, 136.98, 135.77, 132.73 (d, J = 8.9 Hz), 132.56, 
131.33, 126.14, 125.32, 122.58, 117.15 (d, J = 22.0 Hz), 103.43.for [M+Na]+ 
C15H8BrFNaO2
+: 340.9584; found 340.9584. 
4.2.6 (Z)-3-(bromo(4-(trifluoromethyl)phenyl)methylene)isobenzofuran-1(3H)-one 
(QS-M: 6) Yield 67%. 1H NMR (DMSO-d6, 500 MHz) δ 7.99 – 7.94 (m, 3H), 7.85 
(s, 1H), 7.83 (s, 1H), 7.68 – 7.62 (m, 2H), 6.66 – 6.62 (m, 1H). 13C NMR (DMSO-
d6,125 MHz) δ 165.40, 145.36, 140.33, 136.74, 135.88, 131.56, 131.31, 131.04(q, 
J = 11.25 Hz), 126.94 (q, J = 3.75 Hz), 126.24, 125.43, 124.19 (q, J = 268.75 Hz), 
122.57, 102.51. for [M+H]+ C16H9BrF3O2
+: 368.9733; found 368.9733. 
4.2.7 (Z)-3-(bromo(pyridin-2-yl)methylene)isobenzofuran-1(3H)-one (QS-M: 7) 
Yield 48% . 1H NMR (DMSO-d6, 500 MHz) δ 8.78 (d, J = 4.5 Hz, 1H), 8.04 (t, J = 
7.7 Hz, 1H), 7.96 (d, J = 7.3 Hz, 1H), 7.78 (d, J = 7.8 Hz, 1H), 7.71 – 7.55 (m, 3H), 
6.65 (d, J = 7.7 Hz, 1H). 13C NMR (DMSO-d6,125 MHz) δ 165.28, 153.65, 150.67, 
145.79, 138.54, 136.66, 131.61, 126.14, 126.04, 125.50, 125.43, 125.43, 122.94, 
104.07. for [M+Na]+ C14H8BrNNaO2
+: 323.9631; found 323.9631. 
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4.2.8 (E)-3-(bromo(pyridin-2-yl)methylene)isobenzofuran-1(3H)-one (QS-M: 8) 
Yield 32%. 1H NMR (DMSO-d6, 400 MHz) δ 8.72 (d, J = 7.7 Hz, 2H), 8.09 – 7.77 
(m, 5H), 7.44 (m, 1H).13C NMR (,125 MHz) δ 165.56, 153.10, 149.84, 144.72, 
138.51, 136.45, 135.01, 131.26, 126.10, 125.99, 125.95, 125.70, 123.71, 108.37. 
for [M+H]+ C14H9BrNO2
+: 301.9811; found 301.9811. 
4.2.9 (Z)-3-(bromo(pyridin-3-yl)methylene)isobenzofuran-1(3H)-one (QS-M: 9) 
Yield 32% . 1H NMR (DMSO-d6, 400 MHz) δ 8.78 (m, 2H), 8.06 (d, J = 7.9 Hz, 
1H), 7.98 (d, J = 6.5 Hz, 1H), 7.73 – 7.52 (m, 3H), 6.59 (d, J = 7.0 Hz, 1H). 13C 
NMR (CDCl3-d, 100 MHz) δ 165.27, 150.96, 150.26, 145.72, 137.70, 136.79, 
134.69, 130.60, 126.03, 125.78, 122.19, 100.96.for [M+H]+ C14H9BrNO2
+: 
301.9811; found 301.9811. 
4.2.10 (E)-3-(bromo(pyridin-3-yl)methylene)isobenzofuran-1(3H)-one(QS-M: 10) 
Yield 12.8%. 1H NMR (DMSO-d6, 400 MHz) δ 8.88 (s, 1H), 8.67 (d, J = 8.0 Hz, 
1H), 8.61 (d, J = 3.7 Hz, 1H), 8.12 – 7.96 (m, 3H), 7.83 (t, J = 7.4 Hz, 1H), 7.55 (m, 
1H). 13C NMR (CDCl3-d, 125 MHz) δ 165.31, 150.52, 149.59, 143.86, 137.92, 
137.17, 134.82, 131.05, 125.99, 125.60, 125.39, 104.09. for [M+H]+ C14H9BrNO2
+: 
301.9811; found 301.9811. 
4.2.1 (Z)-3-(bromo(pyrimidin-5-yl)methylene)isobenzofuran-1(3H)-one (QS-M: 11) 
Yield 45%. 1H NMR (DMSO-d6, 400 MHz) δ 9.40 (s, 1H), 9.12 (s, 2H), 8.06 – 7.94 
(m, 1H), 7.76 – 7.60 (m, 2H), 6.74 (d, J = 6.8 Hz, 1H). 13C NMR (DMSO-d6,125 
MHz) δ 165.26, 159.72, 158.30, 146.62, 136.58, 136.07, 131.83, 131.38, 126.43, 
125.37, 122.64, 97.16. for [M+H]+ C13H8BrN2O2
+: 302.9764; found 302.9764. 
4.2.12 (E)-3-(bromo(pyrimidin-5-yl)methylene)isobenzofuran-1(3H)-one (QS-M: 
12) Yield 7.6%. 1H NMR (DMSO-d6, 400 MHz) δ 9.21 (s, 1H), 9.13 (s, 2H), 8.68 
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(d, J = 8.0 Hz, 1H), 8.12 – 7.98 (m, 2H), 7.86 (t, J = 7.5 Hz, 1H). 13C NMR (CDCl3-
d,125 MHz) δ 158.15, 158.11, 157.29, 137.56, 135.03, 131.54, 131.18 – 130.93, 
126.20, 125.51, 125.49, 100.05. for [M+H]+ C13H8BrN2O2
+: 302.9764; found 
302.9764. 
4.2. procedure for the preparation of (QS-M: 13) 
Under an argon atmosphere, A (152 mg, 0.5 mmol), HSnBu3(0.07 ml, 0.25 
mmol), Pd(PPh3)4. (58 mg, 0.05 mmol), and THF (4 ml) were added to an oven-
dried Schlenk tube. HSnBu3 (0.07 ml, 0.25 mmol) was added to the stirring mixture 
and then the mixture was heated to 66 oC for 24 h. The reaction mixture was cooled 
to room temperature and extracted with DCM (10 mL), washed brine, dried over 
MgSO4, and filtered. The crude material was purified by flash chromatography on 
silica gel. 
 4.2.1 (Z)-3-(bromomethylene)isobenzofuran-1(3H)-one (QS-M: 13) Yield 25%. 
1H NMR (DMSO-d6, 500 MHz) δ 8.02 (d, J = 7.8 Hz, 1H), 7.93 (d, J = 7.7 Hz, 1H), 
7.87 (t, J = 2.5 Hz,1H), 7.69 (t, J = 7.5 Hz, 1H).13C NMR (CDCl3-d,125 MHz) δ 
165.24, 148.90, 137.94, 134.81, 130.53, 125.86, 124.45, 119.92, 85.63. for [M+H]+ 
C9H6BrO2
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새로운 효과적인 쿼럼센싱 저해제로서의  
브롬화 이소벤조퓨라논 합성 
 
일련의 브롬화 이소벤조퓨라논 유도체를 설계하고 합성하였다. 이 화
합물은 생물막 억제 활성을 가지며 쿼럼센싱 저해제 (QSI)의 좋은 후보 
물질이다. 이들 모두는 두 단계로 간단히 합성할 수 있다. 첫 번째 단계
로 최적인 phthalic anhydride의 디브로모아올레핀화반응은 PPh3를 
P(Oi-Pr)3으로 대체하고 Zn을 첨가하여 진행되었고, 반응 수율을 크게 
증가시켰다. 그 다음에 아릴틴 화합물과 디브로민화 퓨라논 (A)의 Stille 
커플링 후, 주생성물로 Z형 이성질체를 합성하였다. Z 이성질체의 형성
은 1H NMR 분광법과 단결정 X-선 회절을 통해 확인하였다. 일련의 아
릴치환 브로모퓨라논을 제조하고 쿼럼센싱 억제에 대해 시험하였다. 그 
실험된 화합물들 중 페닐치환된 화합물이 가장 활성이 있는 것으로 판
명되었다. 
 
주요어 : 쿼럼센싱 저해제, 치주염, 박테리아 생물막, 브롬화 퓨라논 
